B. Crestani (Paris, France), A. Prasse (Hannover, Germany)
Increased monocyte count and red cell distribution width represent negative prognostic markers in patients with Idiopathic Pulmonary Fibrosis.
T. Karampitsakos (Athens, Greece), S. Torrisi (Heidelberg, Germany), K. Antoniou (Heraklion, Greece), E. Bouros (Athens, Greece), I. Korbila (Athens, Greece), E. Manali (Athens, Greece), E. Vasarmidi (Heraklion, Greece), D. Papakosta (Thessaloniki, Greece), K. Domvri (Thessaloniki, Greece), Z. Daniil (Larissa, Greece), I. Dimeas (Larissa, Greece), P. Kirgou (Larissa, Greece), I. Papanikolaou (Corfu, Greece), E. Bibaki (Heraklion, Greece), K. Markopoulou (Thessaloniki, Greece), G. Kounti (Thessaloniki, Greece), E. Tsapakidou (Thessaloniki, Greece), E. Papadopoulou (Thessaloniki, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), M. Kreuter (Heidelberg, Germany), A. Tzouvelekis (Athens, Greece)
|   |
Monocyte count and decline in forced vital capacity (FVC) in patients with IPF
A. Tzouvelekis (Athens, Greece), T. Maher (London, United Kingdom), N. Goh (Melbourne, Victoria, Australia), M. Kreuter (Heidelberg, Germany), V. Cottin (Lyon, France), B. Schinzel (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), T. Corte (Sydney, New South Wales, Australia)
| |
The role of monocyte count on monitoring patients with Idiopatic Pulmonary Fibrosis under antifibrotic treatment
D. Araújo Barros Coelho (Porto, Portugal), C. Sousa (Porto, Portugal), M. Jacob (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano Mota (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Distinctive polarization of circulating classical monocytes between idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia.
M. Yamashita (Morioka (Iwate Prefecture), Japan), Y. Utsumi (Morioka (Iwate Prefecture), Japan), H. Nagashima (Morioka, Japan), H. Nitanai (Takisawa, Japan), K. Yamauchi (Takisawa, Japan)
| |
Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of anti-fibrotic miR-142-3p
J. Guiot (Liège, Belgium), M. Henket (Liège, Belgium), F. Gester (Liège, Belgium), E. Louis (Liège, Belgium), M. Malaise (Liège, Belgium), R. Louis (Liège, Belgium), I. Struman (Liège, Belgium), S. Njock (Liège, Belgium)
| |
Inflammasome activation in airway macrophages and the lung microbiome in IPF
A. Trachalaki (London, United Kingdom), E. Tsitoura (Heraklion, Greece), R. Invernizzi (London, United Kingdom), S. Mastrodimou (Heraklion, Greece), E. Vasarmidi (Heraklion, Greece), A. Byrne (London, United Kingdom), T. M. Maher (London, United Kingdom), K. Antoniou (Heraklion, Greece), P. L. Molyneaux (London, United Kingdom)
| |
Collagen1a1 mRNA expression in BAL cells is associated with disease progression and poor survival in ILDs
E. Tsitoura (Heraklion, Greece), A. Trachalaki (London, United Kingdom), E. Vasarmidi (Heraklion, Greece), S. Mastrodimou (Heraklion, Greece), M. Kokosi (London, United Kingdom), K. Karagiannis (Heraklion, Greece), G. Margaritopoulos (Manchester, United Kingdom), N. Tzanakis (Heraklion, Greece), A. Wells (London, United Kingdom), K. Antoniou (Heraklion, Greece)
| |
Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression
C. Hayton (Manchester, United Kingdom), D. Terrington (Norwich, United Kingdom), W. Ahmed (Manchester, United Kingdom), I. White (Manchester, United Kingdom), M. Wilkinson (Manchester, United Kingdom), K. Vekaria (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom), A. Wilson (Norwich, United Kingdom), C. Leonard (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom)
| |
Essential trace element levels in IPF patients: a case control study
C. Simsek (Ankara, Turkey), G. Bakici Sari (Ankara, Turkey), B. Akgündüz (Ankara, Turkey), V. Türksoy (Yozgat, Turkey), Y. Agaçkiran (Ankara, Turkey), N. Tezer (Ankara, Turkey), D. Özdemir (Ankara, Turkey)
| |
IgG4 as a potential biomarker of acute exacerbations in ILD
S. Torrisi (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), V. Somogyi (Heidelberg, Germany), M. Polke (Heidelberg, Germany), L. Kehler (Heidelberg, Germany), J. Gauldie (Hamilton, Canada), M. Kreuter (Heidelberg, Germany)
| |
Associations of serological markers of sICAM-1, IL-1ß, MIF and su-PAR with 3-month mortality in acute exacerbation of Idiopathic Pulmonary Fibrosis
X. Li (Nanjing, China), Y. Zhou (Nanjing, China), R. Zou (Nanjing, China), H. Chen (Nanjing, China), . Liu (Nanjing, China), Y. Xiao (Nanjing, China), H. Cai (Nanjing, China), J. Dai (Nanjing, China)
| |
Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD)
E. White (Ann Arbor, Michigan, United States of America), J. Behr (Munich, Germany), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)
| |
Temporal subtraction of serial CT scans for visualisation and quantification of disease progression in Idiopathic Pulmonary Fibrosis
H. Shin (Hannover, Germany), M. Minkler (Hannover, Germany), L. Jaeger (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany), R. Apel (Hannover, Germany), T. Welte (Hannover, Germany), F. Wacker (Hannover, Germany), S. Dettmer (Hannover, Germany), A. Prasse (Hannover, Germany)
| |
Integrative clustering analysis to discover novel IPF disease subtypes in the IPF-PRO Registry
Y. Liu (Ridgefield, Connecticut, United States of America), H. Lin (Pittsburgh, Pennsylvania, United States of America), J. Soellner (Biberach, Germany), J. Roy (Munich, Germany), R. Vinisko (Ridgefield, Connecticut, United States of America), R. Schmid (Biberach, Germany), B. Strobel (Biberach, Germany), J. Belperio (Los Angeles, California, United States of America), J. De Andrade (Nashville, Tennessee, United States of America), K. Flaherty (Ann Arbor, Michigan, United States of America), J. Lasky (New Orleans, Louisiana, United States of America), T. Luckhardt (Birmingham, Alabama, United States of America), M. Neely (Durham, North Carolina, United States of America), C. Hesslinger (Biberach, Germany), S. Palmer (Durham, North Carolina, United States of America), T. Leonard (Ridgefield, Connecticut, United States of America), J. Todd (Durham, North Carolina, United States of America), M. Salisbury (Nashville, Tennessee, United States of America)
| |
Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis
H. Jessen (Herlev, Denmark), N. Hoyer (Copenhagen, Denmark), S. Rønnow (Herlev, Denmark), M. Karsdal (Herlev, Denmark), D. Leeming (Herlev, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark)
| |
Association between MUC5B rs35705950 genotype and response to antifibrotic treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).
E. Cocconcelli (Padova, Italy), D. Biondini (Padova, Italy), N. Bernardinello (Padova, Italy), S. Baraldo (Padova, Italy), S. Lococo (Padova, Italy), G. Andreotti (Padova, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), E. Balestro (Padova, Italy), P. Spagnolo (Padova, Italy)
| |
MUC2MUC5B and TOLLIP variants: no association with disease progression and survival in an IPF cohort
C. Stock (London, United Kingdom), P. Molyneaux (London, United Kingdom), P. Saunders (London, United Kingdom), M. Kokosi (London, United Kingdom), P. George (London, United Kingdom), V. Kouranos (London, United Kingdom), F. Chua (London, United Kingdom), A. Wells (London, United Kingdom), T. Maher (London, United Kingdom), E. Renzoni (London, United Kingdom)
| |